A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 1
50
about 4.9 years
18+
15 sites in CA, DC, FL +8
About this study
Researchers are testing a treatment with glofitamab, gemcitabine, and oxaliplatin for people in the United States who have relapsed or refractory diffuse large B-cell lymphoma. The trial will last about 1798 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Gemcitabine
- 2.Take Glofitamab
- 3.Take Obinutuzumab
- +2 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
gemcitabine, glofitamab, obinutuzumab, oxaliplatin, tocilizumab (Monoclonal antibody; blocks IL-6 receptor to reduce inflammation)
injection (Injection), injection, intravenous, infusion
Primary: Complete response (CR) rate, Incidence of Adverse Events (AEs)
Secondary: Duration of CR, Duration of response (DOR), Objective response rate (ORR), Overall Survival (OS), Progression-free survival (PFS)
Oncology